Downloading...
Download

VBIV

MRNA Taking Profit, Watching for a add LONG after a pullback.MRNA has been on fire since the earnings beat 4 weeks ago and has added 60% to its market cap in the past three months. It compares well with NVAX which as a prior penny stock has more volatility and upside potential. In general vaccine stocks are performing well as COVID RSV and influenza vaccines are active in research are Viral Hepatitis vaccine enhancements and the drive for an HIV vaccine. MRNA is strong and perhaps becoming overbought. The mass index indicator has topped and maybe falling to the trigger line. I will take a one- third partial off my position here and wait for a pullback with reversal to add back into the position at a lower price. The tandem of MRNA and NVAX has been very profitable for me. Careful in trade management will help me keep it that way.
NASDAQ:MRNALong
by AwesomeAvani
Can VBIV jump again like earlier this month?VBIV popped 50 % to begin July and then promptly lost 75% and has been low volume and sideways since. I have not been able to discern any catalyst for that action. Earnings show an ongoing cash burn. In the past couple of days, the Price Volume Trend indicator has detected a small increase in the price volume product. The Relative Trend Index (RTI) indicator has gone from negative to positive on July 18th while the dual time frame RSI indicator showing 1 hour TF in blue and daily TF in black has shown bullish divergence with the lines rising over the 50 level and the blue line above the black line. Price crossed a VWAP band line on July 18th as well. The analysis supports a bullish bias and a set up for a long trade. I will trade long and find an entry on a 15 - 30 minute chart looking for a pivot low to take that position. I will target 2.25 and 3.00 for the time being.
VLong
by AwesomeAvani
1
NVAX Biotechnology Watch Dead Cat Bounce LONGNVAX is fundamentally weak with a shallow pipeline and no products currenly marketed to fund earnings and so research. On the 15 minute chart , NVAX is seen near to its demand zone as shown by the Luxalgo indicator. In the meanwhile, the RSI indicator shows considerable recent strength which is decreased today. So the question is whether NVAX can dead cat bounce with a potential 20% uptrend to reach the supply one or if it instead will break support and continue its descent from a double top April 14-17. I will watch this for the price action to determine whether to take a long trade or short sell this again. Other " vaccine stocks" may be in action as well including VBIV, VCNX, VAXX and MRNA.
NASDAQ:NVAX
by AwesomeAvani
This may be their best batch yet....Looking ready for the buyout.... Best buy is bulding a run.... We hve a bullish formation with some significat top line breaks of a few strong resistance areas. We need a break through 3.60 ...clean and with follow through. This is a low volume stock so any increase in volume creates momentum quite quickly once the big boys start to come in. This is the kind of trade where you will load up slowly to a nice position before the accelaration and dump happens. Good luck!
VLong
by eltraderche
VBIV BUY/LONG NOW READY! 3.30 to 9.60 by End 2022!TICKER CODE: VBIV Company Name: VBI VACCINES, INC US Stocks Health Technology Biotechnology Position Proposed: BUY FOMO BUY ENTRY: NOW READY (3.94) NEXT BUY ENTRY: (3.30) 1st Partial Take Profit: 6.75(End 2021) 2nd Partial Take Profit: 9.60 (End 2022) NOTE THAT THE TIMELINE IS ONLY AN ESTIMATION Stop Loss: 2.80 Technical Analysis 1. LARGE INVERTED HEAD & SHOULDERS PATTERN (Forming 2nd Shoulder) 2. Area of Confluence on EMA & structure level 3. Fibonacci Retracement at 0.786 4. 1st Partial Take Profit is at Fibonacci Extension Level 1 Grey Zone (Safe Zone) - This take profit is also at Key Level 5. 2nd Partial Take Profit will be at level 2 of Fibonacci Expansion Blue Zone. 6. Take Profit will be in the same price range as the Flagpole. Note that there might NOT be a RETEST FOR A RE-BUY ENTRY
VLong
by traderprosignals
1
$VBIV 10 Day MA Reversal and Curl on the Daily10 day MA reversal and curl. Today's candle is just now passing though the 10 day MA but still presents an opportunity for the bears so if the bulls keep the price up we may be able to break this and that should give confirmation of a bullish reversal. Inverted hammer appearing after the series of red candles is indicative that a reversal is about to occur. However, since the next candle did not open above the previous day's close, this indicates the bears may still take control. Further confirmation would be needed to take the trade long.Depending on risk tolerance 2.84-3.02 stop/loss 4.56 target, if it blows past that... woo hoo!
V
by VelvetBarbie
1
Will Run Strong to Earnings Aug 3$VBIV continues to amaze. Just when you think the run is over trader propel this stock higher. Following the old adage - "don't fight the trend" we see VBIV continuing to rise into earnings Aug 3 with brief profit taking along the way. Day traders paradise. Longer term...we're talking weeks...expect VBIV to bask in the glow of being the only self described pan coronavirus vaccine which is a pretty powerful concept. And make no mistake, all of these vaccine makers are dealing with conceptual scientific theories on what will work....so right now, VBIV has just as good a shot at fielding a successful vaccine as the rest. Right now in Robinhood land, 220k RHers hold $INO an early darling in the vaccine race. VBIV only has 60k in following. Given VBIV is comparatively less expensive, I expect to see significant inflows of RH monies into VBIV as it continues it march towards earnings and beyond. Target price prior to earnings a conservative $9.92. If the RH gang catches on could go to $15-18 range and test 5 year highs....worth the time. Remember, "the trend is your friend" and in this red hot biotech space "a rising tide lifts all boats".
VLong
by FindCold
Wall Street is Short VBIV, but I'm Long *Target: [$3.50]*Link to Culper Research report that states they are shorting VBIV because the company is "worthless" img1.wsimg.com First, it's always important to consider ALL information. It's also important to be transparent about knowledge. If you are going to make any VBIV trades you really should read the entire report. 1) I think many of the points made in the Culper Report are legitimate 2) I am not as optimistic about long term price targets as those seen at Guggenheim and on yahoo finance 3) I still believe this is a good short-term trade based on sentiment and momentum regarding June 22-24 release of clinical glioblastoma data Stop loss @ $2.04
VLong
by jfs2152
5